Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Y-mAbs Therapeutics, Inc. (YMAB : NSDQ)
 
 • Company Description   
Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company's product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA.

Number of Employees: 148

 
 • Price / Volume Information   
Yesterday's Closing Price: $10.02 Daily Weekly Monthly
20 Day Moving Average: 644,749 shares
Shares Outstanding: 43.71 (millions)
Market Capitalization: $438.01 (millions)
Beta: 1.48
52 Week High: $39.82
52 Week Low: $6.50
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -14.58% -3.80%
12 Week 25.09% 37.51%
Year To Date -38.19% -25.53%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
230 Park Avenue Suite 3350
-
NEW YORK,NY 10169
USA
ph: 646-885-8505
fax: -
info@ymabs.com http://www.ymabs.com
 
 • General Corporate Information   
Officers
Claus Juan Moller San Pedro - Chief Executive Officer and Director
Thomas Gad - Chairman of the Board of Directors;President
Bo Kruse - Executive Vice President; Chief Financial Officer;
Johan Wedell-Wedellsborg - Director
Laura J. Hamill - Director

Peer Information
Y-mAbs Therapeutics, Inc. (CORR.)
Y-mAbs Therapeutics, Inc. (RSPI)
Y-mAbs Therapeutics, Inc. (CGXP)
Y-mAbs Therapeutics, Inc. (BGEN)
Y-mAbs Therapeutics, Inc. (GTBP)
Y-mAbs Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 984241109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 43.71
Most Recent Split Date: (:1)
Beta: 1.48
Market Capitalization: $438.01 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.68 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.70 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.78
Price/Cash Flow: -
Price / Sales: 10.95
EPS Growth
vs. Year Ago Period: -185.33%
vs. Previous Quarter: 24.71%
Sales Growth
vs. Year Ago Period: 94.80%
vs. Previous Quarter: 9.25%
ROE
03/31/22 - -59.67
12/31/21 - -25.20
09/30/21 - -19.08
ROA
03/31/22 - -51.70
12/31/21 - -22.40
09/30/21 - -16.91
Current Ratio
03/31/22 - 6.12
12/31/21 - 7.26
09/30/21 - 9.09
Quick Ratio
03/31/22 - 5.93
12/31/21 - 7.06
09/30/21 - 8.90
Operating Margin
03/31/22 - -291.89
12/31/21 - -158.40
09/30/21 - -83.21
Net Margin
03/31/22 - -291.89
12/31/21 - -158.40
09/30/21 - -83.21
Pre-Tax Margin
03/31/22 - -291.89
12/31/21 - -158.40
09/30/21 - -83.21
Book Value
03/31/22 - 3.60
12/31/21 - 4.13
09/30/21 - 4.84
Inventory Turnover
03/31/22 - 0.82
12/31/21 - 0.61
09/30/21 - 0.35
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©